Swiss Rockets, MGI US LLC and Complete Genomics Inc. announced  that they entered into a exclusive license agreement with MGI Tech and Complete Genomics, USA, granting Swiss Rockets a perpetual, transferrable, sublicensable, freedom-to-operate, license for USA, Europe, Latam, Africa and Central Asia with option to expand rights into Asia-Pacific in 2026, covering patents and other intellectual property necessary for development, manufacturing, and sales of the next-generation CoolMPS sequencing platform that will provide faster, cheaper and more accurate whole genome sequencing and other omics tests. The agreement includes payments linked to technology transfer and revenue-based royalties.

Swiss Rockets’ future development will focus on advancing CoolMPS products with innovative read barcoding. These innovations will support comprehensive omics testing for advanced genomic research and molecular health monitoring.

CoolMPS chemistry provides the most advanced MPS/NGS generating cost-effective Sanger sequencing quality reads of 600-700bases. It also enables the most accurate typical 150-200b reads. Combined with proprietary co-barcoding libraries the CoolMPS offering comprises complete haplotype-phased genome, transcriptome and microbiome sequencing for both disease prevention and optimal treatment selection, such in cancer detection area.

It also enables the most accurate WGS-based early cancer detection and MRD, when combined with a special sequencing library for cell-free dsDNA allowing to sequence both original strands in one DNA nanoball eliminating almost all false somatic mutations due to DNA damage, or amplification and sequencing errors.

First CoolMPS sequencers, allowing cost-effective SE600+ reads for new applications such as CompleteWGS, CompleteTranscriptome and CompleteMicrobiom are scheduled for early access in Q1 2026

This exciting deal between Swiss Rockets, MGI and Complete Genomics will help us to further develop our breakthrough technology CoolMPS and accomplish our original vision of supporting longer healthy living through omics for all. “This is a dream coming true for me”, said Dr Rade Drmanac, Chief Scientific Officer of MGI and Founder of Complete Genomics, “We now have all that’s needed to utilize full potential of our cutting edge CoolMPS technology.”

“This strategic license partnership with MGI and Complete Genomics perfectly complements Swiss Rockets’ advanced precision therapeutic development companies”, said Vladimir Cmiljanovic, Founder, CEO and Chairman of Swiss Rockets. “It enables us to provide affordable, accurate and informative multi-omics tests in preventive health and early diagnostics, as well as effective treatments in precision medicine and longevity.”